David H. Schubert
General Counsel bei Carmot Therapeutics, Inc.
Profil
David H.
Schubert is currently the Senior Vice President-Regulatory & Quality at Carmot Therapeutics, Inc. He was previously the Vice President at Coley Pharmaceutical Group, Inc., Logical Therapeutics, Inc., MediVector, Inc., and Stealth BioTherapeutics Corp.
He also served as the Senior Vice President-Regulatory & Quality at Chiasma, Inc. from 2020 to 2022.
Schubert completed his undergraduate degree at the University of New Hampshire.
Aktive Positionen von David H. Schubert
Unternehmen | Position | Beginn |
---|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | General Counsel | - |
Ehemalige bekannte Positionen von David H. Schubert
Unternehmen | Position | Ende |
---|---|---|
CHIASMA, INC. | General Counsel | 01.01.2022 |
STEALTH BIOTHERAPEUTICS CORP | Corporate Officer/Principal | 01.07.2020 |
MediVector, Inc. | General Counsel | 01.12.2013 |
Logical Therapeutics, Inc.
Logical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Logical Therapeutics, Inc. develops products that treat diseases associated with inflammation. It provides a platform of bio-activated prodrugs for the chronic treatment of arthritis. Its bio-activated NSAID prodrugs are chemical entities that are designed to reduce the incidence of GI ulcers and improve GI tolerability in patients who require chronic NSAID treatment. The company was founded by Carolyn E. Green in 2005 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01.02.2011 |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Corporate Officer/Principal | - |
Ausbildung von David H. Schubert
University of New Hampshire | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Logical Therapeutics, Inc.
Logical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Logical Therapeutics, Inc. develops products that treat diseases associated with inflammation. It provides a platform of bio-activated prodrugs for the chronic treatment of arthritis. Its bio-activated NSAID prodrugs are chemical entities that are designed to reduce the incidence of GI ulcers and improve GI tolerability in patients who require chronic NSAID treatment. The company was founded by Carolyn E. Green in 2005 and is headquartered in Waltham, MA. | Health Technology |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Health Technology |
Stealth BioTherapeutics Corp.
Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA. | Health Technology |
Chiasma, Inc.
Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
MediVector, Inc. | |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |